Rilzabrutinib dose 1 + Rilzabrutinib dose 2
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Graves' Disease
Conditions
Graves' Disease
Trial Timeline
Sep 2, 2025 → Sep 23, 2026
NCT ID
NCT06984627About Rilzabrutinib dose 1 + Rilzabrutinib dose 2
Rilzabrutinib dose 1 + Rilzabrutinib dose 2 is a phase 2 stage product being developed by Sanofi for Graves' Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06984627. Target conditions include Graves' Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06984627 | Phase 2 | Recruiting |
Competing Products
6 competing products in Graves' Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CFZ533 | Novartis | Phase 2 | 52 |
| RVT-1401 | Immunovant | Phase 2 | 49 |
| IMVT-1402 | Immunovant | Phase 2 | 49 |
| IMVT-1402 + IMVT-1402 + Placebo | Immunovant | Phase 2 | 49 |
| RVT-1401 (Administered via subcutaneous injection) | Immunovant | Phase 2 | 49 |
| IMVT-1402 + IMVT-1402 + Placebo | Immunovant | Phase 2 | 49 |